SOLICITATION NOTICE
B -- DNA methylation, miRNA, and Gene expression Analysis
- Notice Date
- 9/7/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100234-TG
- Archive Date
- 9/30/2010
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6068, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG), Genetic Epidemiology Branch (GEB) plans to procure on a sole source basis DNA methylation, mi RNA and gene expression analyses from Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton Oxford, OX5 1PF UK. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 541380 and the business size standard is $12.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Twelve months from Date of award Dysplastic nevi (DN) is an established risk factor for familial CMM and is highly prevalent in our melanoma families (Tucker et al., 2002); however, the exact molecular mechanisms related to how DN is involved in modifying melanoma risk are not clear. The NCI hypothesizes that potentially distinct at-risk DN epigenetic profile(s) including aberrant genome-wide CpG island methylation, deregulated miRNA profiles and concomitant changes in gene expression may modify melanoma risk in melanoma-prone families with and without known germline mutations. In an earlier procurement, the NCI proposed examining changes in constitutional DNA methylation and miRNA expression signatures as well as correlated influences on global gene expression levels that may be associated with germline CDKN2A mutation status in our melanoma families. Importantly, in the latter study the NCI has already annotated the presence/total number of DN for each of the blood samples (controls and CDKN2A carriers with and without CMM) to be examined. In the present study the NCI aims to evaluate in parallel whether changes in constitutional DNA methylation and miRNA expression signatures as well as any correlated influence on global gene expression levels is associated with DN in melanoma families without CDKN2A mutations. The contractor shall prepare and process seventy two (72) DNA and RNA samples provided by NCI for DNA methylation and miRNA expression signatures, respectively, as well as correlated influences on global gene expression levels that may be associated with DN status in melanoma families without CDKN2A mutations. Three assay types shall be performed: 1) CpG methylation (including preparation and processing of methylated DNA and Agilent 1x244K microarray [ID G4492A containing 27,800 CpG islands covering 21MB]); 2) miRNA microarray (Agilent one 8x15K microarray [human release 14.0], ID number G4471A-025987 containing human and viral miRNAs from the Sanger miRBase); and 3). gene expression Agilent SurePrint G3 Human GE 8x60K Microarray, ID number G4858A-028004 based on updated transcriptome databases for mRNA targets and include probes for long intergenic non-coding RNAs (lincRNAs)). Oxford Gene Technology (OGT) was the first company to be named as a High-Throughput Certified Service Provider (HT CSP) for Agilent microarrays. This new level of the Agilent certification provides official validation of OGT's use of Agilent microarrays in a high-throughput environment and reflects OGT's status as the supplier of choice for large-scale outsourced microarray studies. The certificate was awarded following rigorous assessment of the high-quality experimental data routinely generated by OGT's unique high-throughput analysis service. OGT is the only known source where all analyses - DNA methylation, miRNA and total gene expression - can be performed. Also, Oxford Gene Technology (OGT) shall prepare and process methylated DNA using a highly sensitive and quality assured in-house restriction endonuclease (RE) assay prior to microarray. This validated RE assay is unique (patented) to OGT and circumvents the need for an alternative and costly immunoprecipitation (MeDIP) stage to be carried out by a separate company/provider. Finally, NCI has been using OGT's service for other related projects and it is critical to use the same experimental protocol for direct comparisons. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received at the NCI Office of Acquisitions on or before 11:00 AM EST on September 15, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100234-TG on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100234-TG/listing.html)
- Record
- SN02271150-W 20100909/100908063539-57259670907dd8e8fa8a34abe8c1305c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |